The numbers come first.
The Food and Drug Administration approved Rasonque on Wednesday. The once-daily pill, developed by Revolution Medicines, targets the RAS protein — the mutation that drives tumor growth in roughly 90% to 95% of pancreatic cancer cases and in approximately a quarter of all human cancers.
In the pivotal trial, patients with previously treated metastatic pancreatic adenocarcinoma lived a median of 13.2 months on Rasonque. The comparison arm — standard chemotherapy — delivered 6.7 months. The drug cut the risk of death by 60%. Patients also went longer before disease progression and before pain and quality-of-life scores deteriorated.
The FDA cleared the drug 6.5 months ahead of its user-fee deadline. The agency reviewed the application under its National Priority Voucher pilot program. Rasonque also carries Breakthrough Therapy and Orphan Drug designations. Angelo de Claro, director of the FDA's Oncology Center of Excellence, said the drug 'showed unprecedented results in an area of high unmet need.'
The approval covers adults with metastatic pancreatic adenocarcinoma who have already completed one prior line of treatment or cannot receive combination chemotherapy. No companion diagnostic test is required to identify a specific RAS mutation before prescribing.
Brian Wolpin, the trial's principal investigator and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, said the decision 'gives physicians the confidence that directly inhibiting RAS can make a striking difference for patients.' Anna Berkenblit of the Pancreatic Cancer Action Network called it 'the most significant advance we have seen in the fight against pancreatic cancer.'
The disease earns that language. The American Cancer Society's Cancer Statistics 2026 report estimates 67,530 Americans will be diagnosed with pancreatic cancer this year. About 52,740 will die from it. It is the third-leading cause of cancer death in the United States. Five-year survival sits at 13% — the only major cancer still below 20%. For the roughly 80% of patients diagnosed after the cancer has already spread, five-year survival drops to around 3%.
Revolution Medicines set a list price of $39,800 for a 30-day supply. Eligible insured patients can pay as little as $0 through the company's support program. An expanded access program launched in May has already reached more than 2,000 patients.
The company is already advancing daraxonrasib through late-stage lung cancer trials. RAS mutations appear across lung, colorectal and ovarian cancers as well. Investor Danish Nagda, an early shareholder, told Fortune: 'Instead of developing one drug for just pancreatic cancer, they've actually built an entire platform to go after this core issue called RAS.'
CEO Times take: Free enterprise delivered what decades of public-sector research could not crack alone. A private company bet capital on a target the scientific consensus had labeled 'undruggable.' The market rewarded the discipline. The patient gets an extra six months of life — at minimum. That is the correct order of operations. The FDA's compressed review timeline, enabled by regulatory reforms that brought international oncology reviewers into the process, shows what a leaner administrative state can do when it moves with purpose rather than process. The lesson is transferable well beyond oncology.
